文献速递免疫规划传染病防控与疫情报告

减毒四价登革疫苗KD-382在食蟹猴中诱导持久中和抗体及保护效力

Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys.
PubMed 文献 · Vaccine · 2021-05-01

本研究评估单剂减毒四价登革疫苗KD-382在食蟹猴中的中和抗体持久性及保护效果。单剂接种后四个血清型中和抗体至少持续五年,预存登革免疫不影响四价抗体应答且持续两年以上,异源攻击后病毒RNA低于定量下限,显示完全保护且无疾病增强。

要点

  • 单剂KD-382在食蟹猴诱导四血清型中和抗体至少持续五年。
  • 预存登革免疫不影响KD-382四价中和抗体应答,持续两年以上。
  • 异源攻击后血清病毒RNA低于定量下限,完全保护且无增强。

核心结论

  • KD-382单剂在食蟹猴诱导持久四价中和抗体并实现完全保护,候选可用于登革血清阴性与阳性人群。

研究设计与样本

  • 食蟹猴单剂接种KD-382后长期监测四血清型中和抗体。
  • 部分猴在接种前60天预先给予单价野生型亲本株之一,评估预存免疫影响。
  • 接种猴以不同于预免疫的亲本野生型病毒攻击,检测血清病毒RNA。

主要发现

  • 单剂KD-382诱导针对四个血清型的强中和抗体应答。
  • 四血清型中和抗体滴度至少持续五年。
  • 无论预免疫血清型,所有猴均产生充分四价中和抗体应答并持续两年以上。
  • 异源攻击后血清病毒RNA低于定量下限,无有害疾病增强。

临床怎么用

  • 提示KD-382单剂可能同时适用于登革血清阴性与阳性个体,支持进一步临床开发。

局限性

  • 研究为食蟹猴模型,结果外推至人类需临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An effective dengue vaccine should induce a long-lasting immune response against all four serotypes simultaneously with a minimum number of immunizations. Our live attenuated tetravalent dengue vaccine candidate, KD-382, was developed using a classical host range mutation strategy (no addition of artificial genetic modification). In our previous study, cynomolgus monkeys immunized with a single dose of KD-382 seroconverted to all four serotypes. However, it is important to determine if neutralizing antibodies (NAbs) induced by KD-382 can work as a long-lasting immune response to prevent dengue. In this study, a single dose of KD-382 induced a strong NAb response against all four serotypes in cynomolgus monkeys. We also confirmed that NAb titers against all four serotypes persist for at least five years, indicating its high potential as a dengue vaccine candidate. Next, we evaluated the effect of pre-existing dengue immunity on NAb responses induced by KD-382. We administered KD-382 to cynomolgus monkeys pre-administered one of the monovalent parental wild-type strains 60 days before vaccination. Regardless of the pre-immunized serotype, all the monkeys showed sufficient tetravalent NAb responses, which lasted for over two years. All the KD-382 vaccinated monkeys were then challenged with different parental wild-type viruses than that used for pre-administration; viral RNA in the serum was less than the lower limit of quantification, indicating complete protection against secondary heterologous dengue infection without any harmful disease enhancement. Consequently, KD-382 successfully induced a long-lasting and protective tetravalent NAb response in monkeys, suggesting that KD-382 is a promising vaccine candidate usable for both dengue seronegative and seropositive individuals.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yoshimura M, Shinmura Y, Shishido T, et al. Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys. Vaccine. 2021. PMID: 33941407. doi:10.1016/j.vaccine.2021.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。